Register Login

AVROBIO Inc (AVRO)

REICIN ALISE 🟡 adjusted position in 0 shares (1 derivative) of Tectonic Therapeutic, Inc. (TECX) at $2.38 Transaction Date: Dec 31, 2025 | Filing ID: 000002

Full text
Register to leave comments
  • News bot Jan. 5, 2026, 11:23 p.m.

    🔍 REICIN ALISE (Executive)

    Company: Tectonic Therapeutic, Inc. (TECX)

    Report Date: 2025-12-31

    Transaction Summary:

    • Total transactions: 3
    • Derivative instruments: 1
    • Holdings reported: 1
    • Total shares acquired: 10,966
    • Total shares sold: 10,966
    • Total shares held: 124,530

    Detailed Transactions and Holdings:

    • Acquired 10,966 shares of Common Stock at $2.38 per share (Direct)
      Date: 2025-12-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 239,151.00 | transaction_form_type: 4
    • Holds 0 shares of Common Stock (Direct)
      Date: 2025-12-31 | Code: H | nature_of_ownership: By Trust | shares_owned_after: 124,530.00 | Footnotes: F1
    • Sold 10,966 shares of Employee Stock Option (Right to Buy) at $2.38 per share (Derivative)
      Date: 2025-12-31 | Code: M | Expires: 2031-06-27 | equity_swap_involved: 0 | shares_owned_after: 22,957.00 | transaction_form_type: 4 | Footnotes: F3, F2

    Footnotes:

    • F1: These shares are held by the Reicin-Boiarsky Family Trust (the "Trust"). The Reporting Person's spouse is a co-trustee of the Trust. Accordingly, the Reporting Person may be deemed to have shared voting and dispositive power over the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the shares held by the Trust except to the extent of her pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
    • F2: The shares subject to the option vested as follows: (i) 4,079 shares on June 30, 2024; (ii) 4,078 shares on July 31, 2024, (iii) 4,078 shares on August 31, 2024, (iv) 4,079 shares on September 30, 2024, (v) 4,078 shares on October 31, 2024, (vi) 1,297 shares on November 30, 2024, (vii) 4,078 shares on January 31, 2025, (viii) 4,078 shares on February 28, 2025 and (iv) 4,078 shares on March 31, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date..
    • F3: Received in exchange for a stock option to acquire 63,478 shares of common stock pursuant to that certain merger, as more fully described on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on June 24, 2024. https://www.sec.gov/Archives/edgar/data/1681087/000141588924017952/xslF345X05/form4-06242024_080648.xml

Search

News categories